Dr. Estrov’s research has been focused on the biology and pathobiology of normal and neoplastic hematopoietic cells. His laboratory’s long-range objective is to decipher the pathobiology of hematopoietic neoplasia, focusing on the cross talk between subsets of leukemia cells and their microenvironment, and the mechanisms that provide various leukemia cells with survival and growth advantage. In recent years his laboratory concentrated on the role of the JAK-STAT signaling pathways, their inducible transcriptional activity, and their effects on the growth, survival, plasticity, and apoptosis in normal and hematopoietic neoplastic cells. Dr. Estrov’s team is currently investigating novel means of modulating the activity of those pathways with the aim of developing new strategies for the treatment of myeloproliferative neoplasms (MPN) and chronic lymphocytic leukemia (CLL).